How to access Kesimpta from Abu Dhabi, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-24
A Abu Dhabi patient with relapsing multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting, and active secondary-progressive disease, may receive a prescription for Kesimpta (ofatumumab) from their treating neurologist. Kesimpta is FDA-approved, developed by Novartis, and is a recognised subcutaneous anti-CD20 monoclonal antibody option for relapsing MS. In the Kingdom of Abu Dhabi, Kesimpta is not yet broadly registered for routine outpatient dispensing, and access is typically coordinated through the named-patient import pathway via UAE Ministry of Health and Prevention (MoHAP).
This guide explains the pathway, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Kesimpta is a fully human anti-CD20 monoclonal antibody that depletes B cells. Unlike infusion-based anti-CD20 therapies, Kesimpta is self-administered at home as a subcutaneous injection using a prefilled Sensoready pen. The standard regimen is 20 mg at Weeks 0, 1, and 2 (loading doses), followed by 20 mg once every four weeks thereafter. The at-home dosing profile is a core reason many patients and neurologists select Kesimpta, it preserves patient mobility and reduces infusion-centre demand.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Eligibility requires a confirmed relapsing MS diagnosis per McDonald criteria, MRI evidence, and a rationale for anti-CD20 therapy. Before starting, your neurologist will screen for active or chronic hepatitis B (HBsAg and anti-HBc), verify vaccination status (updating live vaccines before depletion), baseline immunoglobulins, and screen for active infection. During therapy, IgG/IgM monitoring and infection surveillance continue.
Is Kesimpta legally importable into the Abu Dhabi?
Yes, through the MoHAP named-patient import framework. The mechanism permits a the Abu Dhabi-licensed (under DoH) physician to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent registered alternative is suitable for the patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented from the US source to the dispensing site. The Abu Dhabi has a mature named-patient mechanism used routinely across MS and other chronic-therapy categories.
How the pathway works, step by step
- Consultation with your treating neurologist. Confirmation of MS subtype, MRI review, prior DMT history, and clinical rationale for subcutaneous anti-CD20 therapy.
- Pre-treatment screening. Hepatitis B panel, immunoglobulins, vaccination review and update, baseline infection screen.
- MoHAP named-patient application. The physician or hospital pharmacy files the application including clinical rationale, patient reference, product details, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Kesimpta from authorised distribution under DSCSA.
- Cold-chain shipment. Kesimpta ships under validated 2-8 °C cold chain with continuous temperature logging and chain-of-custody documentation.
- Arrival and first dose. The dispensing hospital pharmacy releases the loading-dose pens; the first injection is typically observed at the prescribing facility, with subsequent monthly doses self-administered at home.
What documentation your physician needs
- Clinical rationale letter confirming relapsing MS subtype and Kesimpta as the indicated therapy
- Verification of the DoH medical licence (Abu Dhabi emirate) (SCFHS)
- MRI report supporting the diagnosis
- Hepatitis B screening results and vaccination history
- Baseline immunoglobulin levels
- Planned dosing calendar (Weeks 0, 1, 2 loading; monthly maintenance thereafter)
- Monitoring plan (IgG/IgM, infection surveillance)
Reserve Meds provides a physician documentation kit bundling templates MoHAP reviewers expect for anti-CD20 MS named-patient imports.
Typical costs and indicative timing
Kesimpta's US cash-pay reference cost sits in an indicative 2026 annual range of roughly USD 90,000-110,000 depending on the year and loading versus maintenance period. Cold-chain international logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. These figures are indicative drug-only reference pricing.
Indicative timing for first dose after cohort intake opens is 7-14 days from the moment a complete MoHAP application is submitted. Monthly refills, once the pathway is established, are generally faster.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A brief culturally-aware note: Ramadan and Hajj seasons can affect scheduling and refill timing. Our concierge team coordinates your monthly cycle with your family's preferences and travel plans.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review.
- Logistics. Validated cold-chain shipment to your prescribing hospital.
- Concierge case lead. A named point of contact coordinating monthly refills.
What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
What to monitor on Kesimpta
Kesimpta sits in the anti-CD20 class with Ocrevus (ocrelizumab) and Briumvi (ublituximab) but differs in route: monthly subcutaneous self-injection rather than intravenous infusion. Four safety signals stand out for the patient and the treating neurology team: serious infections including hepatitis B reactivation, persistent hypogammaglobulinaemia, injection-related reactions (systemic and local), and progressive multifocal leukoencephalopathy as a class consideration. Each is described below with the monitoring cadence and the prescribing-information citation.
Serious infections and hepatitis B reactivation. Upper respiratory tract infections were the most common adverse event in the ASCLEPIOS I and II trials (Hauser SL et al., N Engl J Med 2020;383(6):546-557). The Kesimpta label warns of serious bacterial, fungal, and new or reactivated viral infections, including hepatitis B virus reactivation, which can be fatal (Kesimpta Prescribing Information, section 5.2). Pre-treatment screening for hepatitis B is mandatory: HBsAg and anti-HBc (total) at minimum. Patients with chronic hepatitis B require hepatology co-management and antiviral prophylaxis. Patients with resolved hepatitis B need a frank discussion of reactivation risk and a monitoring plan. Active infection at the time of a scheduled dose warrants delaying that dose until the infection has resolved. Reference: Kesimpta (ofatumumab) Prescribing Information, Novartis, section 5.2.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Kesimpta label calls for measurement of quantitative serum immunoglobulins before initiation of Kesimpta, periodically during treatment, and after discontinuation until B-cell repletion (Kesimpta Prescribing Information, section 5.3). MS-experienced centres typically check IgG, IgA, and IgM at baseline and every six months once a patient is established on therapy. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Kesimpta Prescribing Information, section 5.3; ASCLEPIOS I and II, N Engl J Med 2020.
Injection-related reactions. Unlike infusion-based anti-CD20 therapies, Kesimpta is administered as a subcutaneous self-injection using a prefilled Sensoready pen, so reactions are classified as injection-related rather than infusion-related. Two distinct patterns are described in the prescribing information (Kesimpta Prescribing Information, section 5.1): systemic injection-related reactions (fever, headache, myalgia, chills, fatigue) within 24 hours of injection, which were most common after the first dose and decreased markedly with subsequent doses; and local injection-site reactions (erythema, pain, swelling, pruritus). The first injection is given under healthcare supervision; subsequent monthly doses are self-administered at home once patient training is complete. No routine premedication is required, but paracetamol may be considered for symptom management of systemic reactions. Severe reactions, including anaphylaxis, require permanent discontinuation. Reference: Kesimpta Prescribing Information, section 5.1; APLIOS bioequivalence study, Bar-Or A et al., MS Journal 2022.
Progressive multifocal leukoencephalopathy (PML) as a class consideration. No PML cases have been reported with ofatumumab in the MS development programme to date, but the Kesimpta label notes PML as a class effect of anti-CD20 therapies, including post-marketing cases reported with other agents in the class (Kesimpta Prescribing Information, Warnings and Precautions). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Baseline JC virus antibody serology is not mandated by the FDA label but is sometimes obtained for risk stratification in patients with prior immunosuppressive exposure. Reference: Kesimpta Prescribing Information, Warnings and Precautions.
Frequently asked
Is this legal in Abu Dhabi? Yes, when executed through the MoHAP named-patient framework with appropriate documentation. See our trust and compliance page.
Is Kesimpta truly self-administered at home? Yes, after the first observed injection and patient training, subsequent monthly doses are self-administered using the Sensoready prefilled pen. Your neurologist confirms patient suitability.
How does Kesimpta compare with Ocrevus or Briumvi? All three are anti-CD20 therapies. Kesimpta is monthly subcutaneous; Ocrevus is six-monthly IV; Briumvi is IV with shorter infusion times. Your neurologist selects based on disease activity, logistics, and patient preference.
Why hepatitis B screening? Anti-CD20 therapy can reactivate latent hepatitis B, so pre-treatment screening is mandatory under FDA labeling.
Will private insurance cover this? Cash-pay is the default. Some Abu Dhabi private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-24.